Compare Quest Diagnostics Inc (DGX) vs Global Payments Inc (GPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Global Payments Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Global Payments Inc trades at $82.2 (market cap $21.46B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Global Payments Inc for 50 Days on average.
| DGX | GPN | |
|---|---|---|
Market Cap | $25.48B | $21.46B |
Volume | 941,866 | 1,482,600 |
Sector | Health | Financials |
52-Week High | $247.45 | $94.83 |
52-Week Low | $173.49 | $62.47 |
Typical Hold Time | 56 Days | 50 Days |
Enterprise Value | $31.23B | $39.60B |
Dividend Yield | 1.49% | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Global Payments (GPN) trades at $82.20, up 1.38% with neutral technical signals. The stock shows strong earnings momentum with three consecutive quarterly beats, though faces profitability challenges with negative net margins. Recent developments include the Genius platform rollout and Worldpay integration driving growth potential. Valuation metrics show a P/E of 38.43 and P/B below book value at 0.93, while analyst consensus remains bullish with a $102.75 price target.
Investment outlook balances growth catalysts from digital payment expansion against rising costs and competitive pressures. The 24% upside to consensus target offers potential reward, but investors must weigh debt levels increasing to 41.57% debt-to-asset ratio and projected 2026 net loss against strategic initiatives. Near-term performance hinges on Q3 earnings delivery and Genius adoption metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
